cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Novo Nordisk defends disappointing next-gen

Observed Heart Rate Changes: Increase of 5-10 beats per minute during treatment Peak increase around week 24, then gradual decline Persists but diminishes through week 68 Why This Happens: Sympathetic nervous system activation Increased metabolic rate from weight loss Direct effects on cardiac tissue Clinical Significance: Modest heart rate increases (5-10 bpm) don't appear harmful in clinical trials

It is quite easy to administer, without any timing restrictions related to food or time of day

doi: 10.4049/jimmunol.2300293 61 HothersallJSGordgeMNoronha-DutraAA

Most patients stay on GLP-1 programs for 6-12+ months